Bionano Genomics, Inc. Q2 2026 Earnings Call Summary
Bionano Genomics reported Q2 2026 results on an earnings call, citing 30% YoY consumables growth and record 53% adjusted gross margin from higher adoption and efficiency. Full-year 2026 revenue guidance was raised to $31M-$33M. Flow-cell backorders and manufacturing constraints are expected to ease by Q4 2026. Software revenue fell 16% YoY.
How this was made
The 30-second read
Why it matters
Traders can update expectations for revenue conversion from backlog into recognized sales based on the company’s stated plan to remedy flow-cell backorders by mid-to-late Q4 2026, plus a Q4 2026 Ionic system expansion target.
Market read
The key tradable items are the raised FY 2026 revenue guidance range, Q3 2026 guidance range, and the operational timeline for clearing flow-cell constraints, all tied to demand and order timing.
What to watch
Software revenue declined 16% YoY due to deployment timing delays, which could pressure longer-term recurring revenue quality even if consumables growth remains strong.
Background
This is a Q2 2026 earnings call summary for Bionano Genomics, focusing on growth drivers, guidance, and operational constraints in flow-cell manufacturing.
Ticker impact
Bionano Genomics raised full-year 2026 revenue guidance to $31M-$33M and expects flow-cell backorders to ease by mid-to-late Q4 2026.
Moderately positive bias for the next few sessions as traders price in improved demand-to-supply conversion, with volatility around Q3 order timing.
The article provides specific guidance ranges (FY and Q3) and concrete operational assumptions (backorder remediation timing, Q4 Ionic expansion), which are actionable for positioning. However, it does not include the actual reported quarter numbers, limiting precision on magnitude.
Market effects
Signals ongoing demand for OGM consumables and software transition, which may influence sentiment toward digital pathology and genomics tooling suppliers.
Highlights Europe-led adoption, suggesting regional reimbursement/coverage dynamics are supporting growth.
Backlog and manufacturing constraints are a cross-market supply-chain issue that can affect broader instrument and consumables demand expectations.
Counterpoint
Raised guidance only at the low end, with management explicitly capping upside until manufacturing capacity catches up, implying upside may be delayed rather than eliminated.
Key entities
- companyBionano Genomics, Inc.
OGM platform and consumables provider raising FY 2026 guidance and addressing flow-cell manufacturing backorders.
- executiveDr. Alex Hastie
Returned as Chief Scientific Officer to reinforce scientific leadership for clinical research applications.
